Articles tagged with Type 1 Diabetes
Children diagnosed with type 1 diabetes are at significantly higher risk of mood and anxiety disorders, as well as behavioral syndromes. The study highlights the urgent need for monitoring and support for their mental health.
A follow-up study found that COVID-19 infection accelerated the progression from pre-symptomatic to clinical type 1 diabetes in youth, with no observed effect in adults. Further research is needed to determine whether vaccination and monitoring for COVID-19 symptoms can help prevent or delay this progression.
Researchers identified two distinct T-cell signatures in children with newly diagnosed type 1 diabetes and those at risk of developing the disease. These signatures may serve as potential biomarkers and targets for preventive immunotherapy treatments.
Researchers from Mount Sinai and City of Hope demonstrate a combination treatment that increases human insulin-producing beta cells by 700% in mice with diabetes. This breakthrough could lead to new treatments for the hundreds of millions of people with diabetes worldwide.
A six-year study found that consuming diets more closely aligned with the Mediterranean and DASH diets can lower levels of harmful blood markers and reduce cardiovascular disease risk. These dietary patterns emphasize plant-based foods, healthy fats, lean proteins, and low intake of processed foods and sugars.
The number of people aged 65 and older with type 1 diabetes increased from 1.3 million to 3.7 million between 1990 and 2019, while death rates fell by 25%. However, substantial global inequalities in diabetes care persist, with higher mortality rates in low- and middle-income countries.
A new study led by researchers at UC San Francisco found that a virtual emotion-centered program called TunedIn can reduce diabetes distress by half and improve glucose control. The program incorporates elements of Acceptance and Commitment Therapy and was delivered virtually to 276 adults with Type 1 diabetes.
Aging human pancreatic beta cells display features of senescence but maintain elevated levels of genes crucial for function and exhibit an ability to release insulin in response to glucose. This sheds light on the potential role of aging beta cells in immune regulation and their relevance to autoimmune reactions in type 1 diabetes.
A new study aims to investigate whether vaccination against SARS-CoV-2 can protect children at increased genetic risk of developing type 1 diabetes. The AVAnT1A Study, the largest intervention study to date, examines the relationship between viral infections and early childhood development.
A new NIH grant will investigate biological processes that contribute to defects in immune response in the eyes of those with diabetes. Researchers aim to understand why diabetic patients are more susceptible to corneal infections and identify methods to reverse these effects.
Researchers have discovered a repurposed cancer drug that can convert acinar cells into insulin-producing cells, which could provide a new avenue for treating diabetes. The treatment partially improved hyperglycemia and persisted without additional treatment in diabetic mice and non-human primates.
An experimental monoclonal antibody drug called mAb43 appears to prevent and reverse the onset of clinical type 1 diabetes in mice, lengthening their lifespan. The drug targets insulin-making beta cells directly and shields them from immune system attacks, raising the possibility of a new treatment for the autoimmune condition.
Adults with type 1 diabetes who use modern hybrid insulin pumps experience significant improvements in blood sugar levels, reducing the risk of organ damage by up to three hours per day. The treatment also reduces the time spent with low blood sugar levels and is associated with high patient satisfaction.
Researchers found a unique genetic mutation in the PD-L1 gene, essential for preventing autoimmune diabetes. The discovery sheds light on the role of PD-L1 in regulating immune cells and could lead to new treatments for the devastating disease.
A low-fat vegan diet was found to reduce insulin needs by 28% and improve insulin sensitivity by 127% in people with type 1 diabetes, according to a groundbreaking new study. The diet also led to improvements in cholesterol levels, kidney function, and weight.
Studies at the University of Gothenburg found a clear shift in arterial disease risks in diabetes, with decreases in central organ diseases like heart attack and stroke, but increases in peripheral vessel complications. Closer monitoring of long-term blood sugar levels can reduce peripheral arterial disease risk by 30-50%.
Leading investigators are creating a one-stop resource for human pancreatic data, standardizing and disseminating curated information on the human pancreas to foster collaborative and reproducible diabetes research. The PanKbase program aims to provide machine-actionable data following FAIR principles.
Researchers found that a high-fat diet suppresses the expression of a key protein in the gut, leading to inflammation and increased risk of Alzheimer's. Managing diabetes may be key to preventing or slowing down dementia symptoms.
A new study evaluates the use of tirzepatide in overweight/obese adults with type 1 diabetes, showing significant weight loss and improved glucose control. Tirzepatide also reduces insulin dose and increases time-in-range on continuous glucose monitoring.
Women with selected rheumatic diseases experience a higher prevalence of childlessness, while risks for pre-eclampsia, low birth weight, and preterm delivery are increased for many conditions. Men with rheumatic conditions also face a higher risk of childlessness, although the impact on fertility varies among different diseases.
Researchers have developed a novel immunotheraphy targeting macrophages to induce tolerance in type 1 diabetes, demonstrating its potential as a curative treatment. The therapy also shows promise for other autoimmune diseases, with results suggesting no impact on the immune system's ability to capture and process liposomes.
A new study reveals that glucose fluctuations affect cognitive function in people with Type 1 Diabetes, but individuals differ in their susceptibility. The researchers found that minimizing glucose fluctuations is crucial for optimizing processing speed, especially for older adults and those with certain health conditions.
The University of Arizona College of Medicine – Tucson has received a $2.7 million grant from the Juvenile Diabetes Research Foundation to test an implantable device that could eliminate the need for glucose testing and insulin injections in people with Type 1 diabetes. The device, developed by Professor Klearchos Papas, uses oxygen-en...
Groundbreaking research reveals changes in pancreatic beta cells at the onset of Type 1 Diabetes, identifying a novel mechanism for protection and a promising therapeutic target in mice and humans. Boosting levels of METTL3 enzyme may slow disease progression.
Healthcare providers must prioritize patient experience to improve diabetes care. This includes explaining treatment options and considering each patient's level of health literacy and cultural background.
A study found that 670 nanometres of red light stimulated energy production within mitochondria, leading to increased glucose consumption and a 27.7% reduction in blood glucose levels. This non-invasive technique has the potential to impact diabetes control by reducing damaging fluctuations of blood glucose.
A multicenter study found that a small pancreas size predicts a faster progression to stage 3 Type 1 diabetes. The study also suggests that using pancreas volume measurement combined with validated metabolic risk measures can more accurately predict disease development than either method alone.
A global study review found negative indirect impacts of the pandemic on people with diabetes, including a rise in non-COVID-19-related deaths, diabetic ketoacidosis among children and adolescents, and sight loss. Pediatric ICU admissions were also significantly increased.
Researchers have developed a new oral insulin medicine that uses nano-carriers to protect insulin from stomach acid, allowing for precise delivery to the liver and reducing the risk of hypoglycemia. This innovation has been successfully tested on baboons, mice, and rats with diabetes, paving the way for human trials starting in 2025.
A new study published in Nature Communications found that AI-driven eye exams can close care gaps among racial and ethnic minority youth with diabetes, populations with historically higher rates of diabetic retinopathy. The technology uses cameras to take pictures of the back of the eye without dilation and provides immediate results.
Researchers have successfully genetically modified pluripotent stem cells to evade immune recognition, offering a viable path forward for pluripotent stem cell-based therapies. The study's findings suggest that these engineered stem cells could pave the way for new treatments for diseases such as Type 1 diabetes and macular degeneration.
A study of 620,000 children found that maternal type 1 diabetes was associated with increased risk for most types of congenital heart defects in offspring. Obesity and overweight were linked to increased risk for complex defects, such as outflow tract obstruction, while decreasing the risk for ventricular septal defects.
A recent study by the Hebrew University proposes a new etiology for early stages of type 1 diabetes, attributing it to disrupted RNA editing within pancreatic beta cells. This perspective challenges long-held beliefs about viral involvement, suggesting potential implications for treatments and cures.
A moderate low-carbohydrate diet has been shown to lower average blood sugar levels and increase time spent within the target glucose range without adverse effects. Participants experienced improved glucose control and felt more satisfied with the new diet.
A world-first human trial shows that a commonly prescribed rheumatoid arthritis drug can safely and effectively preserve the body's own insulin production and suppress the progression of type 1 diabetes. The drug, baricitinib, was found to be effective in maintaining insulin production in people who initiated treatment within 100 days ...
Researchers found that vaccination of neonatal mice with group A Streptococcus promotes clonal expansion of innate-like B cells producing antibody against N-acetyl-D-glucosamine (GlcNAc), reducing Type 1 diabetes risk. These GlcNAc-specific B-1 B cells aid in producing tolerance, facilitating efficient clearance of apoptotic beta cells...
The international consensus report on precision diabetes medicine highlights significant advancements in prevention, diagnosis, treatment, and prognosis. The report also sheds light on knowledge gaps and provides a framework for future research.
Researchers from Cornell and University of Alberta have developed an under-the-skin implant that can secrete insulin without immunosuppression. The approach offers an easier alternative to traditional transplants or insulin injections, with the potential for long-term management of Type I diabetes.
Researchers at the University of Alberta and Cornell University have developed a device that can secrete insulin under the skin, improving cell survival and diabetes reversal in mice. The innovative approach called SHEATH avoids immunosuppression, making transplants safer for patients with type 1 diabetes.
A new clinical trial has shown that a stem cell-based device can reduce the amount of insulin required for some participants with Type 1 diabetes. The device, developed by ViaCyte, aims to replace the insulin-producing beta cells that people with the condition lack.
Researchers analyzed FDA and patent records to find that manufacturers extended market exclusivity by filing additional patents after FDA approval and obtaining patents on delivery devices. This resulted in a median of 16 years of protection, surpassing other top-selling small-molecule drugs.
Researchers discover a unique gene, ZNF808, crucial for human pancreas development, contrasting with its absence in other animals. This finding could aid the search for a Type 1 diabetes cure by understanding how humans differ from other species.
Researchers are developing a bioengineered pancreas-like tissue using innovative biomaterials and engineered cells. The goal is to implant these cell-laden scaffolds into patients who need help managing their glucose levels.
A comprehensive review study identifies emerging biomarkers that mirror efforts to halt beta-cell autoimmunity, offering potential applications in clinical practice. The study's findings may improve the management of type 1 diabetes during its partial remission phase.
A team of MSU researchers, supported by a $750,000 grant from JDRF, is creating a new approach to image immune cells in living subjects. This could enable better treatment opportunities and outcomes for patients with Type 1 diabetes, particularly those who are eligible for cell transplantation strategies.
Researchers at the University of Alberta have created a new process to produce insulin-producing pancreatic cells from patient stem cells, achieving a 90% success rate. The breakthrough could lead to injection-free glucose control in people with diabetes and eliminate the need for anti-rejection drugs.
A new Cochrane review has found that human insulin can be stored at room temperature for up to six months without losing potency. This breakthrough research offers hope to millions of people living with diabetes in low- and middle-income countries, particularly those with limited access to refrigeration or healthcare.
A recent study presents exciting future possibilities for managing type 1 diabetes with the repurposed drug α-difluoromethylornithine (DFMO), which may reduce insulin dependency. The researchers have established preliminary safety of DFMO for individuals with type 1 diabetes, paving the way for innovative therapies.
A new study provides preliminary evidence that an existing drug, α-difluoromethylornithine (DFMO), could be used to treat type 1 diabetes. The drug has already been FDA-approved for other indications and may offer a more convenient treatment option for patients.
A new phase 3 clinical trial found that once-weekly basal injection of icodec to treat type 1 diabetes showed non-inferiority to daily insulin degludec in reducing HbA1C levels. However, higher rates of hypoglycaemic episodes were noted in the icodec group.
A new study published in the University of East Anglia shows that automated insulin delivery technology can help pregnant women with type 1 diabetes better manage their blood sugars. The technology, known as Hybrid Closed-Loop or Artificial Pancreas, helps to substantially reduce maternal blood sugars throughout pregnancy.
A new study shows that closed-loop use in type 1 diabetes during pregnancy leads to improved glycemic control and reduced risks. Women using closed-loop technology reported better sleep and fewer worries about their baby's health.
A new study found that hybrid closed-loop technology significantly improved maternal blood sugars in pregnant women with type 1 diabetes. Women who used the technology spent more time within the target range for pregnancy blood sugar levels, gained less weight, and had fewer complications.
A new study published in Diabetologia found that hybrid closed-loop technology improved maternal blood sugars during pregnancy complicated by type 1 diabetes. The technology, which adjusts insulin doses every 10-12 minutes, helped reduce maternal blood sugar levels and weight gain, while also improving baby health outcomes.
The Second International Consensus Report on Precision Diabetes Medicine addresses the need for personalized approaches in diabetes care. The report highlights the potential of precision medicine to improve prevention and treatment outcomes by accounting for disease heterogeneity.
A study published in JAMA Network Open found a persistent increase in psychotropic medication dispensation among children and adolescents with type 1 diabetes. The findings highlight the need for integrated pediatric diabetes care and mental health services to detect psychological needs early on.
Research suggests that universal screening for type 1 diabetes at two ages could predict most cases of T1D by age 15. Dr. Emily K. Sims emphasizes the importance of identifying individuals with early, presymptomatic stages of disease to prevent life-threatening episodes and improve outcomes.
A phase 1/2 study shows that a stem cell-derived islet therapy has improved blood sugar control in all six adult patients with type 1 diabetes. Three patients achieved insulin independence and showed sustained improvements in blood glucose levels.
A recent US study has found that food insecurity significantly increases the risk of severe hypoglycaemia in adults with diabetes. The study, which analyzed data from over 1,000 participants, revealed that those experiencing food insecurity were nearly twice as likely to experience severe hypoglycaemic events.
A study of over 1 million Swedish men found that high blood pressure at age 18 was associated with a higher risk of major cardiovascular events, including heart failure, heart attacks, and strokes. Early intervention for hypertension may be critical to reducing later cardiovascular events.